8-K
Concentra Group Holdings Parent, Inc. (CON)
View as plain text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
_______________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 7, 2025
_______________
CONCENTRA GROUP HOLDINGS PARENT, INC.
(Exact Name of Registrant as Specified in Its Charter)
_______________
001-42188
(Commission File Number)
| Delaware | 30-1006613 |
|---|---|
| (State or Other Jurisdiction of Incorporation) | (I.R.S. Employer Identification No.) |
5080 Spectrum Drive, Suite 1200W
Addison, TX, 75001
(Address of principal executive offices) (Zip code)
(972) 364-8000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value per share | CON | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2025, Concentra Group Holdings Parent, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2025. A copy of the press release and financial schedules are attached as Exhibit 99.1 to this report and incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation published by the Company on May 7, 2025 in connection with its press release announcing its financial results for its first quarter ended March 31, 2025.
The information in this Current Report on Form 8-K (including Exhibit 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 8.01 Other Events.
Dividend Declaration
On May 6, 2025, the Company’s Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable on or about May 29, 2025 to stockholders of record as of the close of business on May 20, 2025.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description |
|---|---|
| 99.1 | Press Release, dated May 7, 2025, announcing financial results for the first quarter ended March 31, 2025 and cash dividend. |
| 99.2 | Concentra Group Holdings Parent, Inc. Presentation. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CONCENTRA GROUP HOLDINGS PARENT, INC. | ||
|---|---|---|
| Date: May 7, 2025 | By: | /s/ Timothy Ryan |
| Timothy Ryan | ||
| Executive Vice President and Chief Legal Counsel |
Document
| NEWS RELEASE | | --- || FOR IMMEDIATE RELEASE | | --- |
Concentra Group Holdings Parent, Inc. Announces Results
For Its First Quarter Ended March 31, 2025, Cash Dividend, and Revised FY 2025 Guidance
ADDISON, TEXAS — May 7, 2025 — Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services, today announced results for its first quarter ended March 31, 2025, and the declaration of a cash dividend.
“Concentra reported a solid start to 2025 with strong revenue and Adjusted EBITDA growth in the first quarter. With a deep understanding of patient and client needs and market dynamics, we continue to execute on key drivers of growth and deliver a comparative market advantage. Maintaining this focus ensures we continue to achieve our strategic business objectives for the year,” said Keith Newton, Chief Executive Officer of Concentra.
Matt DiCanio, Concentra’s President & Chief Financial Officer, added, “We are very pleased with the organic and inorganic growth developments at the outset of 2025, including the first positive year-over-year growth in Employer Services visit volumes in several quarters. We successfully closed the Nova Medical Centers acquisition and launched three de novo centers in the first quarter, and in April signed a definitive agreement to acquire Pivot Onsite Innovations. We remain focused and confident in our ability to achieve an effective and efficient integration of these centers and businesses through our organizational design and operational efficiency, providing great momentum as we progress in 2025.”
First Quarter 2025 Highlights
•Revenue of $500.8 million, an increase of 7.1% from $467.6 million in Q1 2024
•Net income of $40.6 million, and earnings per common share of $0.30 in Q1 2025
•Adjusted earnings per common share of $0.32 in Q1 2025
•Adjusted EBITDA of $102.7 million, an increase of 6.8% from $96.1 million in Q1 2024
•Cash balance of $52.1 million and net leverage of 3.9x at the end of Q1 2025
•Patient Visits of 3,204,368, or 50,863 Visits per Day in the quarter, an increase in Visits per Day of 3.2% from Q1 2024
•Revenue per Visit of $146.94, an increase of 5.6% from $139.09 in Q1 2024
•Total occupational health centers of 627, compared to 547 at the end of Q1 2024
•Total onsite health clinics of 160, compared to 151 at the end of Q1 2024
First Quarter 2025 Financial Overview
For the first quarter ended March 31, 2025, revenue increased 7.1% to $500.8 million, compared to $467.6 million for the same quarter, prior year. Income from operations increased 6.4% to $80.3 million for the first quarter ended March 31, 2025, compared to $75.5 million for the same quarter, prior year. Net income was $40.6 million and earnings per common share was $0.30 for the first quarter ended March 31, 2025 compared to net income of $50.3 million and earnings per common share of $0.47, for the same quarter, prior year. Net income decreased due to higher interest expense from the IPO recapitalization. Adjusted earnings per common share was $0.32 for the first quarter ended March 31, 2025, compared to $0.49 for the same quarter, prior year. Adjusted EBITDA increased 6.8% to $102.7 million for the first quarter ended March 31, 2025, compared to $96.1 million for the same quarter, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table VII of this release. The definition of adjusted earnings per share and a reconciliation of net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis are presented in table VIII of this release.
Balance Sheet
As of March 31, 2025, our balance sheet reflected cash of $52.1 million, total debt of $1,634.2 million and total assets of $2,729.2 million. Concentra’s net leverage ratio as of March 31, 2025 is 3.9x, which was in compliance with the financial covenant under our credit agreement. The Company is targeting a net leverage ratio of approximately 3.0x within 18-24 months.
Cash Flow
Cash flows provided by operating activities in the first quarter ended March 31, 2025 totaled $11.7 million compared to $44.6 million for the same quarter, prior year. The decline in year over year cash flow from operations is largely attributable to a $28.2 million increase in interest payments following the recapitalization of the Company in July 2024 in conjunction with Concentra’s IPO. During the first quarter ended March 31, 2025, cash flow from investing activity resulted in cash used of $294.7 million, including capital expenditures of $15.7 million and acquisition-related spend of $279.0 million. Cash flow from operations less cash flow from investing activity resulted in cash used of $283.1 million for the quarter. Cash flow from financing activity generated $151.9 million for the quarter, resulting in a decrease in cash of $131.1 million.
Nova Acquisition Closing
Effective March 1, 2025, the Company acquired Nova Medical Centers (“Nova”) for a purchase price of $265 million, subject to adjustment in accordance with the terms and conditions set forth in the equity purchase agreement.
Nova operates 67 occupational health centers in five states, providing workers’ compensation injury care services, physical therapy, drug and alcohol screening, and pre-employment physicals as part of their full suite of occupational health services. The process of integrating Nova into Concentra’s network of occupational health centers is off to a strong start, which will help us strengthen the delivery of quality care and exceptional service through greater access, while also resulting in accelerated innovation and enhanced outcomes for patients, customers and employers.
The transaction was financed using a combination $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
Debt Financing
On March 3, 2025, the Company completed an amendment to the Credit Agreement to increase our Revolving Credit Facility by $50.0 million from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid. In addition, the amendment to the Credit Agreement also added new debt through an incremental term loan of $102.1 million, which provides an updated Term Loan of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including 25-basis point step down at a net leverage ratio of ≤3.25x.
Pivot Onsite Innovations
On April 18, 2025, Concentra Health Services, Inc. (“CHS”), a wholly owned subsidiary of the Company, entered into an equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Onsite Innovations, LLC (“Pivot Onsite Innovations”). The transaction values Pivot Onsite Innovations at $55 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. The transaction is expected to close in the second quarter of 2025 and is subject to customary closing conditions set forth in the purchase agreement.
CHS currently expects to finance the announced transaction using a combination of cash on hand and available borrowing capacity under its existing revolving credit facility.
Pivot Onsite Innovations operates approximately 200 onsite health clinics at employer locations in over 40 states, providing occupational health, wellness, prevention, and performance services. When combined with Concentra’s
current onsite health clinic footprint, the acquisition will enable the Company to expand to more than 350 onsite health clinics at employer worksites.
Dividend
On May 6, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable May 29, 2025, to stockholders of record as of the close of business on May 20, 2025.
There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of the Board of Directors after taking into account various factors, including, but not limited to, the Company’s financial condition, operating results, available cash and current and anticipated cash needs, the terms of indebtedness, and other factors the Board of Directors may deem to be relevant.
2025 Business Outlook
Concentra raised its financial guidance for 2025, based on strong Q1 results and additional development activity. For 2025, Concentra now expects to deliver the following results:
•Revenue in the range of $2.1 billion to $2.15 billion
•Adjusted EBITDA in the range of $415 million to $430 million
•Capital expenditures in the range of $80 million to $90 million (no change from initial guidance)
•Net leverage ratio of approximately 3.5x (no change from initial guidance)
A reconciliation of full year 2025 Adjusted EBITDA expectations to net income is presented in table IX of this release.
Company Overview
Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our approximately 12,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 50,000 patients each day on average across 45 states at our 627 occupational health centers, 160 onsite health clinics at employer worksites, and Concentra Telemed as of March 31, 2025.
Conference Call
Concentra will host a conference call regarding its first quarter financial results and business outlook on Thursday May 8, 2025, at 9 a.m. Eastern Time. The conference call will be a live webcast and can be accessed via this Earnings Call Webcast Link or via Concentra’s website at https://ir.concentra.com. A replay of the webcast will be available shortly after the call at the same locations.
Participants may join the audio-only version of the webcast or participate in the question-and-answer session by calling:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access: All dial-in participants should ask to join the Concentra call.
* * * * *
Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Concentra’s 2025 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:
•The frequency of work-related injuries and illnesses;
•The adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks;
•Changes to regulations, new interpretations of existing regulations, or violations of regulations;
•State fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors;
•Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs;
•Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs;
•Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers;
•A security breach of our, or our third-party vendors’, information technology systems which may cause a violation of HIPAA and subject us to potential legal and reputational harm;
•Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes;
•Significant legal actions could subject us to substantial uninsured liabilities;
•Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements;
•Insurance coverage may not be sufficient to cover losses we may incur;
•Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities;
•Our exposure to additional risk due to our reliance on third parties in many aspects of our business;
•Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting;
•Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information;
•Compliance with applicable data interoperability and information blocking rule;
•Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations;
•Our ability to adequately protect and enforce our intellectual property and other proprietary rights;
•Adverse economic conditions in the U.S. or globally;
•Any negative impact on the global economy and capital markets resulting from other geopolitical tensions;
•The impact of impairment of our goodwill and other intangible assets;
•Our ability to maintain satisfactory credit ratings;
•The effects of the Separation on our business;
•Our ability to achieve the expected benefits of and successfully execute the Separation and related transactions;
•Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the Separation and related transactions;
•The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease similar to the COVID-19 pandemic;
•The loss of key members of our management team;
•Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of our senior management;
•Climate change, or legal, regulatory or market measures to address climate change;
•Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters;
•Changes in tax laws or exposures to additional tax liabilities; and
•Changes to United States tariff and import/export regulations and the impact on global economic conditions may have a negative effect on our business, financial condition and results of operations.
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.
Investor inquiries:
Bill Chapman
Vice President, Strategy & Investor Relations
972-725-6488
ir@concentra.com
SOURCE: Concentra Group Holdings Parent, Inc.
I. Condensed Consolidated Statements of Operations
For the Three Months Ended March 31, 2025 and 2024
(In thousands, except per share amounts, unaudited)
| Three Months Ended March 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | % Change | ||||
| Revenue | $ | 500,752 | $ | 467,598 | 7.1 | % |
| Costs and expenses: | ||||||
| Cost of services, exclusive of depreciation and amortization | 357,101 | 336,990 | 6.0 | |||
| General and administrative, exclusive of depreciation and amortization(1) | 46,713 | 36,909 | 26.6 | |||
| Depreciation and amortization | 16,619 | 18,485 | (10.1) | |||
| Total costs and expenses | 420,433 | 392,384 | 7.1 | |||
| Other operating income | — | 284 | (100.0) | |||
| Income from operations | 80,319 | 75,498 | 6.4 | |||
| Other income and expense: | ||||||
| Loss on early retirement of debt | (875) | — | N/M | |||
| Interest expense | (25,548) | (111) | N/M | |||
| Interest expense on related party debt | — | (9,971) | N/M | |||
| Income before income taxes | 53,896 | 65,416 | (17.6) | |||
| Income tax expense | 13,254 | 15,137 | (12.4) | |||
| Net income | 40,642 | 50,279 | (19.2) | |||
| Less: net income attributable to non-controlling interests | 1,731 | 1,323 | 30.8 | |||
| Net income attributable to the Company | $ | 38,911 | $ | 48,956 | (20.5) | % |
| Basic and diluted earnings per common share(2) | $ | 0.30 | $ | 0.47 |
_____________________________________
(1) Includes transaction services agreement fees of $3.7 million for the three months ended March 31, 2025, and shared service fees from a related party of $3.8 million for the three months ended March 31, 2024.
(2) Refer to table II for calculation of earnings per common share.
N/M Not meaningful
II. Earnings per Share
For the Three Months Ended March 31, 2025 and 2024
(In thousands, except per share amounts, unaudited)
As of March 31, 2025, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the three months ended March 31, 2025, the Company applied the two-class method because its unvested restricted shares were participating securities.
As of March 31, 2024, the Company’s capital structure consists of common stock and there were no participating shares or securities outstanding.
The following table sets forth the net income attributable to the Company, its shares, and its participating shares:
| Basic and Diluted EPS | ||||
|---|---|---|---|---|
| Three Months Ended March 31, | ||||
| 2025 | 2024 | |||
| (in thousands) | ||||
| Net income | $ | 40,642 | $ | 50,279 |
| Less: net income attributable to non-controlling interests | 1,731 | 1,323 | ||
| Net income attributable to the Company | 38,911 | 48,956 | ||
| Less: distributed and undistributed income attributable to participating securities | 455 | — | ||
| Distributed and undistributed income attributable to common shares | $ | 38,456 | $ | 48,956 |
The following table sets forth the computation of EPS. The Company applied the two-class method for the three months ended March 31, 2025.
| Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Attributable to the Company | Shares(1) | Basic and Diluted EPS | Net Income Attributable to the Company | Shares(1) | Basic and Diluted EPS | |||||
| (in thousands, except for per share amounts) | ||||||||||
| Common shares | $ | 38,456 | 126,647 | $ | 0.30 | $ | 48,956 | 104,094 | $ | 0.47 |
| Participating securities | 455 | 1,500 | $ | 0.30 | — | — | $ | — | ||
| Total Company | $ | 38,911 | $ | 48,956 |
____________________________________________
(1) Represents the weighted average shares outstanding during the period.
III. Condensed Consolidated Balance Sheets
(In thousands, unaudited)
| March 31, 2025 | December 31, 2024 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash | $ | 52,109 | $ | 183,255 |
| Accounts receivable | 258,128 | 217,719 | ||
| Prepaid income taxes | 1,392 | 1,544 | ||
| Other current assets | 39,960 | 34,689 | ||
| Total current assets | 351,589 | 437,207 | ||
| Operating lease right-of-use assets | 463,032 | 435,595 | ||
| Property and equipment, net | 207,271 | 197,930 | ||
| Goodwill | 1,444,563 | 1,234,707 | ||
| Other Identifiable intangible assets, net | 249,788 | 204,725 | ||
| Other assets | 12,995 | 11,000 | ||
| Total assets | $ | 2,729,238 | $ | 2,521,164 |
| LIABILITIES AND EQUITY | ||||
| Current liabilities: | ||||
| Current operating lease liabilities | $ | 96,301 | $ | 75,442 |
| Current portion of long-term debt and notes payable | 15,758 | 10,093 | ||
| Accounts payable | 35,188 | 19,752 | ||
| Dividends payable | 8,010 | — | ||
| Accrued and other liabilities | 165,134 | 201,899 | ||
| Total current liabilities | 320,391 | 307,186 | ||
| Non-current operating lease liabilities | 405,914 | 396,914 | ||
| Long-term debt, net of current portion | 1,618,473 | 1,468,917 | ||
| Non-current deferred tax liability | 24,362 | 25,380 | ||
| Other non-current liabilities | 29,037 | 24,043 | ||
| Total liabilities | 2,398,177 | 2,222,440 | ||
| Redeemable non-controlling interests | 18,609 | 18,013 | ||
| Stockholders’ equity: | ||||
| Common stock, $0.01 par value, 700,000,000 shares authorized, 128,171,952 and 128,125,952 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 1,282 | 1,281 | ||
| Capital in excess of par | 263,105 | 260,837 | ||
| Retained earnings | 44,454 | 13,553 | ||
| Accumulated other comprehensive loss | (1,722) | — | ||
| Total stockholders’ equity | 307,119 | 275,671 | ||
| Non-controlling interests | 5,333 | 5,040 | ||
| Total equity | 312,452 | 280,711 | ||
| Total liabilities and equity | $ | 2,729,238 | $ | 2,521,164 |
IV. Condensed Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2025 and 2024
(In thousands, unaudited)
| Three Months Ended March 31, | ||||
|---|---|---|---|---|
| 2025 | 2024 | |||
| Operating activities | ||||
| Net income | $ | 40,642 | $ | 50,279 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | 16,619 | 18,485 | ||
| Loss on extinguishment of debt | 51 | — | ||
| (Gain) loss on sale of assets | (1) | 43 | ||
| Stock compensation expense | 2,269 | 166 | ||
| Amortization of debt discount and issuance costs | 976 | — | ||
| Deferred income taxes | (1,028) | (2,521) | ||
| Other | 11 | 12 | ||
| Changes in operating assets and liabilities, net of effects of business combinations: | ||||
| Accounts receivable | (21,145) | (13,505) | ||
| Other current assets | (2,753) | (7,315) | ||
| Other assets | 902 | 722 | ||
| Accounts payable and accrued liabilities | (24,844) | (1,744) | ||
| Net cash provided by operating activities | 11,699 | 44,622 | ||
| Investing activities | ||||
| Business combinations, net of cash acquired | (279,018) | (5,144) | ||
| Purchases of property and equipment | (15,732) | (17,231) | ||
| Proceeds from sale of assets | 1 | 23 | ||
| Net cash used in investing activities | (294,749) | (22,352) | ||
| Financing activities | ||||
| Borrowings on revolving facilities | 50,000 | — | ||
| Borrowings from related party revolving promissory note | — | 10,000 | ||
| Payments on related party revolving promissory note | — | (10,000) | ||
| Proceeds from term loans, net of issuance costs | 948,848 | — | ||
| Payments on term loans | (847,875) | — | ||
| Borrowings of other debt | 6,468 | 6,618 | ||
| Principal payments on other debt | (4,695) | (2,276) | ||
| Distributions to and purchases of non-controlling interests | (842) | (1,543) | ||
| Distributions to Select | — | (6,891) | ||
| Net cash provided by (used in) financing activities | 151,904 | (4,092) | ||
| Net (decrease) increase in cash | (131,146) | 18,178 | ||
| Cash at beginning of period | 183,255 | 31,374 | ||
| Cash at end of period | $ | 52,109 | $ | 49,552 |
| Supplemental information | ||||
| Cash paid for interest | $ | 38,137 | $ | 9,958 |
| Cash (refund received) paid for taxes | $ | (48) | $ | 34 |
V. Key Statistics
For the Three Months Ended March 31, 2025 and 2024
(unaudited)
| Three Months Ended<br><br>March 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | |||||
| Facility Count | ||||||
| Number of occupational health centers—start of period | 552 | 544 | ||||
| Number of occupational health centers acquired | 72 | 2 | ||||
| Number of occupational health centers de novos | 3 | 1 | ||||
| Number of occupational health centers closed/sold | — | — | ||||
| Number of occupational health centers—end of period | 627 | 547 | ||||
| Number of onsite health clinics operated—end of period | 160 | 151 | ||||
| The following table sets forth operating statistics for our occupational health centers operating segment for the periods presented: | ||||||
| Three Months Ended <br>March 31, | ||||||
| 2025 | 2024 | % Change | ||||
| Number of patient visits | ||||||
| Workers’ compensation | 1,444,880 | 1,433,084 | 0.8 | % | ||
| Employer services | 1,696,412 | 1,659,291 | 2.2 | % | ||
| Consumer health | 63,076 | 63,280 | (0.3) | % | ||
| Total | 3,204,368 | 3,155,655 | 1.5 | % | ||
| Visits per day volume | ||||||
| Workers’ compensation | 22,935 | 22,392 | 2.4 | % | ||
| Employer services | 26,927 | 25,926 | 3.9 | % | ||
| Consumer health | 1,001 | 989 | 1.2 | % | ||
| Total | 50,863 | 49,307 | 3.2 | % | ||
| Revenue per visit(1) | ||||||
| Workers’ compensation | $ | 209.09 | $ | 195.29 | 7.1 | % |
| Employer services | 94.40 | 90.84 | 3.9 | % | ||
| Consumer health | 136.52 | 131.57 | 3.8 | % | ||
| Total | $ | 146.94 | $ | 139.09 | 5.6 | % |
| Business days(2) | 63 | 64 |
_____________________________________
(1) Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers segment and does not include our onsite health clinics or other businesses segments.
(2) Represents the number of days in which normal business operations were conducted during the periods presented.
VI. Disaggregated Revenue
For the Three Months Ended March 31, 2025 and 2024
(In thousands, unaudited)
The following table disaggregates the Company’s revenue for the three months ended March 31, 2025 and 2024:
| Three Months Ended <br>March 31, | ||||
|---|---|---|---|---|
| 2025 | 2024 | |||
| (in thousands) | ||||
| Occupational health centers: | ||||
| Workers' compensation | $ | 302,107 | $ | 279,866 |
| Employer services | 160,140 | 150,735 | ||
| Consumer health | 8,611 | 8,326 | ||
| Other occupational health center revenue | 2,064 | 2,145 | ||
| Total occupational health center revenue | 472,922 | 441,072 | ||
| Onsite health clinics | 16,550 | 15,857 | ||
| Other | 11,280 | 10,669 | ||
| Total revenue | $ | 500,752 | $ | 467,598 |
VII. Net Income to Adjusted EBITDA Reconciliation
For the Three Months Ended March 31, 2025 and 2024
(In thousands, unaudited)
Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures that we believe provide useful insight into the underlying performance of our business by excluding items that may obscure trends in our core operating results. These metrics are not intended to be substitutes for GAAP measures such as net income and may differ from similarly titled metrics supported by other companies. We use these non-GAAP measures internally for budgeting, forecasting, and evaluating performance. Investors should consider these measures in addition to, and not as a replacement for, GAAP results reported in our financial statements.
Adjusted EBITDA is a supplemental measure that we believe offers a clearer view of business performance by excluding items that do not reflect the core operations of the Company. We define adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, stock-based compensation expense, acquisition related costs, gains or losses on early retirement of debt, separation transaction costs, gains or losses on the sale of businesses, and equity in earnings or losses from unconsolidated subsidiaries. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by total revenue. This margin helps assess the efficiency of our operations on a normalized basis.
The following table reconciles net income to Adjusted EBITDA and net income margin to Adjusted EBITDA margin and should be referenced when we discuss Adjusted EBITDA and Adjusted EBITDA margin.
| Three Months Ended March 31, | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | |||||||
| ($ in thousands) | Amount | % of Revenue | Amount | % of Revenue | ||||
| Reconciliation of Adjusted EBITDA: | ||||||||
| Net income | $ | 40,642 | 8.1 | % | $ | 50,279 | 10.8 | % |
| Add (Subtract): | ||||||||
| Income tax expense | 13,254 | 2.6 | 15,137 | 3.2 | ||||
| Interest expense | 25,548 | 5.1 | 111 | — | ||||
| Interest expense on related party debt | — | — | 9,971 | 2.1 | ||||
| Loss on early retirement of debt | 875 | 0.2 | — | — | ||||
| Stock compensation expense | 2,269 | 0.5 | 166 | — | ||||
| Depreciation and amortization | 16,619 | 3.3 | 18,485 | 4.0 | ||||
| Separation transaction costs(1) | 315 | 0.1 | 1,993 | 0.5 | ||||
| Nova acquisition costs | 3,137 | 0.6 | — | — | ||||
| Adjusted EBITDA | $ | 102,659 | 20.5 | % | $ | 96,142 | 20.6 | % |
_____________________________________
(1) Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.
VIII. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share
For the Three Months Ended March 31, 2025 and 2024
(In thousands, except per share amounts, unaudited)
Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share are used by management to provide useful insight into the underlying performance of our business in each of our operating segments. Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share are not measures of financial performance under U.S. GAAP and are not intended to be substitutes for U.S. GAAP measures such as net income or earnings per common share. These metrics may differ from similarly titled metrics supported by other companies. Concentra believes that the presentation of Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share are important to investors because they are reflective of the financial performance of Concentra’s ongoing operations and provide better comparability of its results of operations between periods. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reported in our financial statements.
We define Adjusted Net Income Attributable to Common Shares as net income attributable to common shares, excluding gain (loss) on early retirement of debt, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and other non-recurring costs not directly tied to operating performance. We define Adjusted Earnings per Common Share as the Adjusted Net Income Attributable to Common Shares divided by the diluted weighted average common shares outstanding.
The following table reconciles net income attributable to common shares and earnings per common share on a fully diluted basis to Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share on a fully diluted basis.
| Three Months Ended March 31, | ||||||||
|---|---|---|---|---|---|---|---|---|
| ($ in thousands, except per share amounts) | 2025 | Per Share(1) | 2024 | Per Share(1) | ||||
| Reconciliation of Adjusted Net Income Attributable to Common Shares: | ||||||||
| Net income attributable to common shares(1) | $ | 38,456 | $ | 0.30 | $ | 48,956 | $ | 0.47 |
| Adjustments:(2) | ||||||||
| Loss on early retirement of debt | 865 | 0.01 | — | — | ||||
| Separation transaction costs(3) | 311 | — | 1,993 | 0.02 | ||||
| Nova acquisition costs | 3,100 | 0.02 | — | — | ||||
| Total additions, net | $ | 4,276 | $ | 0.03 | $ | 1,993 | $ | 0.02 |
| Less: tax effect of adjustments(4) | (1,052) | (0.01) | (460) | — | ||||
| Adjusted Net Income Attributable to Common Shares | $ | 41,680 | $ | 0.32 | $ | 50,489 | $ | 0.49 |
| Weighted average common shares outstanding - diluted | 126,647 | 104,094 |
_____________________________________
(1) Net income attributable to common shares and earnings per common share are calculated based on the diluted weighted average common shares outstanding in table II.
(2) Reflects the common shares allocation of the adjustments.
(3) Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.
(4) Tax impact is calculated using the annual effective tax rate, excluding discrete costs and benefits.
IX. 2025 Net Income to Adjusted EBITDA Reconciliation
Business Outlook for the Year Ending December 31, 2025
(In millions, unaudited)
The following is a reconciliation of full year 2025 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure. Refer to tables VII for discussion of Concentra's use of Adjusted EBITDA in evaluating financial performance and for the definition of Adjusted EBITDA. Each item presented in the below table is an estimation of full year 2025 expectations.
| Range | ||||
|---|---|---|---|---|
| ($ in millions) | Low | High | ||
| Net income attributable to the Company | $ | 162 | $ | 173 |
| Net income attributable to non-controlling interests | 6 | 6 | ||
| Net income | $ | 168 | $ | 179 |
| Income tax expense | 56 | 60 | ||
| Interest expense | 108 | 108 | ||
| Stock compensation expense | 10 | 10 | ||
| Depreciation and amortization | 69 | 69 | ||
| Nova acquisition costs | 4 | 4 | ||
| Adjusted EBITDA | $ | 415 | $ | 430 |
14
conq12025investorpresent
©2025 Concentra Inc. All rights reserved. 1st Quarter 2025 Results May 7, 2025
©2025 Concentra Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements that express the Company’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to, financial guidance and other projections and forecasts. Forward looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those under “Risk Factors” therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond the Company’s control. Any forward looking statement made by the Company in this presentation speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in this presentation. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward looking statements and you should not place undue reliance on its forward looking statements. The Company’s forward looking statements do not reflect the potential impac t of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions it may make. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Use of Non-GAAP Financial Information In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including reconciliations of these non-GAAP measures to their most directly comparable GAAP measures, which are included in this presentation, as well as in the Company’s quarterly financial press releases and re lated Form 8-K filings with the SEC. This information can be accessed for free by visiting www.concentra.com or www.sec.gov. We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies. We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, Nova acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We will refer to Adjusted EBITDA and Adjusted EBITDA margin throughout these materials. Disclaimer 2
©2025 Concentra Inc. All rights reserved. Concentra At-a-Glance 3 Concentra is the largest provider of occupational health services in the United States by number of locations1, with a mission of improving the health of America’s workforce, one patient at a time KEY STATISTICS 160 Onsite health clinics1 ~12k Total colleagues & affiliated clinicians1,3 $1.9bn TTM Revenue1 19.8% TTM Adj. EBITDA margin1,4 45 States with service offerings1 ~215k Employer customers2 ~50,000 Patients cared for each business day2 ROBUST FINANCIALS* $383mm TTM Adj. EBITDA1,4 <1% Revenue from government payor reimbursement2 >80% Free cash flow conversion2,5 627 Occupational health centers1 <3% Revenue from largest employer customer2,6 (1) As of March 31, 2025; (2) As of TTM March 31, 2025; (3) The term "colleagues and affiliated physicians and clinicians" includes both our directly employed colleagues who provide administrative and management support to the affiliated professional medical group entities and the physicians and clinicians that are employed by the affiliated professional medical groups; (4) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income; (5) Free cash flow (“FCF”) calculated as FCF divided by Adjusted EBITDA, FCF is calculated as Adjusted EBITDA minus purchases of property and equipment, and is a non-GAAP measure; (6) Excludes Nova occupational health centers *Does not include annualized impact of Nova and PHC acquisitions, recent de novos, or pending acquisition of Pivot Onsite Innovations
©2025 Concentra Inc. All rights reserved. We Continue to Deliver on Goals & Key Initiatives 4 Strong Q1 performance with robust YoY growth in Revenue (+7.1%) and Adj. EBITDA (+6.8%), despite one less revenue day Announced the acquisition of Pivot Onsite Innovations (200+ onsite health clinics) on April 21st Reiterated de-levering target of ~3.5x by year-end 2025, and ~3.0x in 18-24 months $0.0625 quarterly dividend maintained, continuing to return value to shareholders Opened three de novos in Q1 2025 with 3-4 more expected to open by the end of year Positive year-over-year volume growth, including within Employer Services; trend has continued into Q2 2025 Raising FY 2025 Revenue guidance to $2.100bn-$2.150bn and FY 2025 Adj. EBITDA guidance to $415mm-$430mm Completed acquisitions of Nova (+67 centers) and PHC (+5 centers) with smooth integration to date Successful re-financing and re-pricing of senior debt and upsizing of revolver Operational / Financial Development Capital Allocation Hedged interest rates on $600mm of notional TLB, resulting in 75%+ of total outstanding debt at fixed rate or hedged
©2025 Concentra Inc. All rights reserved. 5 Q1 2025 Performance (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income; (2) Excluding acquisitions Q1 2024 Q1 2025 YoY (∆) Commentary Facility Count (end of period) Occupational Health Centers 547 627 +80 Due to Nova acquisition (+67) and other M&A and de novos Onsite Health Clinics 151 160 +9 KPIs Visits per Day (“VPD”) 49.3k 50.9k 3.2% +0.6% Workers’ Compensation VPD 22.4k 22.9k 2.4% +0.2% VPD growth excluding impact of Nova acquisition Employer Services VPD 25.9k 26.9k 3.9% +0.9% Revenue per Visit (“RPV”) $139.09 $146.94 5.6% Workers’ Compensation RPV $195.29 $209.09 7.1% Employer Services RPV $90.84 $94.40 3.9% Financials ($ in millions) +8.9% Revenue growth on a per-day basis Total Revenue $467.6 $500.8 7.1% +6.3% Revenue growth on a per-day basis excluding Nova (Note: One less revenue day in Q1 2025 vs. Q1 2024)Net Income $50.3 $40.6 (19.2%) Net Income margin 10.8% 8.1% (270)bps Total Adj. EBITDA1 $96.1 $102.7 6.8% Normalizing Q1 2024 for a one-time expense reversal, Adj. EBITDA margin increased from 19.8% in Q1 2024 to 20.5% in Q1 2025 Adj. EBITDA margin1 20.6% 20.5% (6)bps Capital Expenditure2 $17.2 $15.7 (8.7%)
©2025 Concentra Inc. All rights reserved. 6 We Deliver High Quality Service to Employers and Patients Through Multiple Access Points Occupational Health Centers Onsite Health Clinics Telemed # of Facilities1 627 160 (excluding Pivot Onsite Innovations) Virtual 24/7 Customer Base and Types Each center serves hundreds of employers ~215,000 employers, ranging from Fortune 100 to small businesses Each clinic dedicated to a single employer’s worksite Medium to large-sized companies All types of employers % of Revenue2 ~95% ~3% (excluding Pivot Onsite Innovations) ~1% Key Services Workers’ Compensation Employer Services Consumer Health Advanced Primary Care (employer-sponsored) Growth Developments ✓ 72 centers acquired in Q1 via Nova and PHC transactions (TX, GA, TN, WI, IN, FL) ✓ 3 de novos opened in Q1 (TX, IL) ✓ Signed definitive agreement to acquire Pivot Onsite Innovations (~200 clinics) ✓ Continued growth of advanced primary care service offering (launched Q3 2024) ✓ Continued ramp of behavioral health service offering (launched Q3 2024) (1) As of March 31, 2025; (2) TTM as of March 31, 2025, figures are rounded, remaining percentage comprised of other businesses (pharmacy repackaging operations and third-party employer services administration)
©2025 Concentra Inc. All rights reserved. Combined Locations ~200 160 ~360 Revenue ~$60M $64M $120M+ States 41 36 43 Colleagues2 700+ ~460 1,200+ Years of Experience 27 32 59 Accelerating Growth Through the Acquisition of Pivot Onsite Innovations 7 Key Stats1 Key Investment Highlights Transforms Concentra Onsite Health into the leading occupational health-focused provider of onsite clinics in the U.S.3 Proven integration playbook, which will position Pivot Onsite Innovations to deliver long-term growth and success within Concentra Highly compelling and tangible synergy and cross-sell opportunities between Concentra and Pivot Onsite Innovations Doubles size of Concentra’s onsite health clinics segment, amplifying ability to deliver accessible occupational health and advanced primary care to large employersx2 Highly complementary fit with Concentra Onsite Health; fully aligned with Concentra’s business, mission, and growth strategy (1) Pivot Onsite Innovations figures as of February 2025, Concentra figures as of December 2024 (except 160 locations as of 3/31/25); (2) Includes full-time, part-time, and PRN colleagues; (3) Estimated based on number of occupational health-focused onsite health clinic locations ▪ $55 million purchase price, subject to certain customary adjustments ▪ Expect to fund with cash-on-hand and available liquidity under existing revolver ▪ Expect to close in Q2 2025, subject to customary closing conditions Transaction Terms ▪ Immediately accretive to Concentra’s earnings; projected < 9x EBITDA multiple by Year 2 (post-synergy) ▪ Previous CON leverage targets of ~3.5x by YE 2025 and <3.0x within 18-24 months remain intact, pro forma for deal Key Considerations
©2025 Concentra Inc. All rights reserved. 8 We Have a Highly Diverse Business with Strong Underlying Fundamentals and Minimal Stroke-of-the-Pen Risk (1) Occupational Health Center revenue, TTM as of March 31, 2025; (2) Based on occupational health centers operated by Concentra as of March 31, 2025; (3) Excludes Nova occupational health centers. Percentages represent rounded approximations and may not total 100%. Broad geographic mix2 Remaining States 52% Texas 16% California 16% Florida 6% Pennsylvania 5%Colorado 4% Attractive payor mix1 Employer Services Employers and TPAs 33% Medicare & Other <1% Workers’ Compensation Employers, insurance carriers and TPAs 65% Urgent & Commercial 2% Diverse industry mix1,3 Retail, 10% Manufacturing, 9% Healthcare, 9% Construction, 8% Business Services & Staffing Agencies, 8% Logistics & Motor Freight, 7%Wholesale, 7% Government*, 7% Food Stores, Products & Restaurants, 7% Transportation, 7% Schools, 5% Other, 18% Low employer customer concentration1,3 ~37% Top 1,000 Employers Remaining Employers 63% #2 - #1,000 Employers ~34% #1 Employer <3% *Largely comprised of local/state government entities ~99% non-government payor = minimal stroke-of-the-pen risk
©2025 Concentra Inc. All rights reserved. ⚫~1% of revenue comes from government reimbursement (e.g., Medicare, Medicaid) ⚫Workers’ Compensation reimbursement rates are pre-determined by state fee schedules or UCR guidelines, and not beholden to state budgets; Employer Services reimbursement determined by negotiated, market-based pricing between employer or TPA and Concentra ⚫Consistent reimbursement rate increases over time across both Workers’ Compensation and Employer Services: ~3+% CAGR in rate increases 2016 – 2024 Regulatory & Reimbursement Exposure Labor Pressures ⚫Staffing model does not rely on the type of labor that has historically seen the greatest inflationary pressures (e.g., registered nurses) ⚫Cost of services historically represents consistent percentage of revenue; trend supported by state fee schedules, UCR guidelines and market-based pricing with employers including CPI escalators Economic Uncertainty and Tariffs ⚫Labor and cost structure allow for rapid adaptation to real time market conditions: ⚫ Global Financial Crisis & COVID-19 Pandemic: resilient performance through adjustments to cost structure, matching decrease in visit volumes experienced; optimized cash flow and CapEx; Concentra maintained EBITDA margins through downturns ⚫ Tariffs: Diversified supply chain and relatively minimal operational reliance on medical supplies & pharmacy (< 3% of revenue), mute potential direct impact of tariffs on CON profitability Employment Trends & Growth ⚫ Ability to effectively serve populations across the country as employment trends shift via nationwide footprint and proven track record operating across heterogenous markets; re-shoring of companies in U.S. likely to be a tailwind for CON ⚫ Flexible and sophisticated growth strategy allows for deliberate and targeted growth, including active de novo development and tuck-in M&A pipeline We Have A Long-Demonstrated Track Record Of Navigating Broader Macroeconomic Turbulence 9
©2025 Concentra Inc. All rights reserved. Balance Sheet & Capital Allocation Strategy 10 M&A and De Novos Strategic, impactful acquisitions (Nova, PHC, Pivot Onsite Innovations) + consistent de novo expansion = short- and long-term value creation Leverage Prudent management of leverage levels, targeting ~3.0x net leverage in 18-24 months Capital Expenditures Continued strategic investment in technology, facilities, and infrastructure Dividend Concentra Board of Directors approved a quarterly cash dividend of $0.0625 per share Risk Management Hedged interest rates via swaps and collars on $600mm of notional term loan B, resulting in 75%+ of total outstanding debt with protection from potential increases in rate Net Leverage Liquidity $52 $386 $438 3/31/2025 Cash Revolver Capacity3 ($ in millions) (1) Net Leverage = Net Debt / Adjusted EBITDA (non-GAAP measure, see appendix for a reconciliation of Adjusted EBITDA to net income); (2) Calculation in compliance with the financial covenant under the credit agreement; (3) Concentra has $50 million of outstanding borrowings under its $450 million revolving facility; however, Concentra has $386.4 million of availability under its revolving credit facility after giving effect to $13.6 million of outstanding letters of credit Capital Allocation Strategy (Net leverage as multiple of Adj. EBITDA1) Nova acquisition Heightened focus on acquisition integration and de-levering for remainder of 2025 ~3.9x 3.5x 3.9x ~3.5x ~3.0x At IPO FY '24A 3/31/2025 FY '25E In 18-24 Months 2
©2025 Concentra Inc. All rights reserved. Revised 2025 Full-Year Guidance 11(1) Adjusted EBITDA is a non-GAAP measure, see appendix for a reconciliation to net income; (2) Net Leverage = Net Debt / Adjusted EBITDA (non-GAAP measure, see appendix for a reconciliation of Adjusted EBITDA to net income) FY 2024 Actual Original FY 2025 Guidance Revised FY 2025 Guidance YoY Growth (%) Total Revenue $1,900.2mm $2.1bn $2.1bn – $2.15bn 10+% Adjusted EBITDA1 $376.9mm $410mm – $425mm $415mm – $430mm 10+% Capital Expenditures $65.7mm $80mm – $90mm $80mm – $90mm Net Leverage2 3.5x ~3.5x ~3.5x Guidance Commentary • Updating previous guidance from early March announcement • Given strong start to 2025 and growth efforts, we are raising our Revenue and Adjusted EBITDA ranges • No change to Capital Expenditures and Net Leverage outlook • Monitoring economic situation • Likely to share updated view in Q2 or subsequent months
©2025 Concentra Inc. All rights reserved. Appendix
©2025 Concentra Inc. All rights reserved. 13 Our Long-Term Financial Targets Consistent Profitability with Continued Improvement 20%+ Adjusted EBITDA margin1 Robust Free Cash Flow2 Generation >80% Annual FCF conversion2 Prudent Deleveraging Strategy ~3.0x Targeted net leverage3 in 18-24 months Stable Revenue Growth Mid-to-High Single-digit growth Dividend $0.0625 Quarterly cash dividend per share Note: These are not projections; they are goals/targets and are forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these goals/targets will be achieved and the Company undertakes no duty to update its goals/targets; (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures; (2) Calculated as free cash flow (“FCF”) divided by Adjusted EBITDA, FCF is calculated as Adjusted EBITDA minus purchases of property and equipment, and is a non-GAAP measure; (3) Net Leverage = Net Debt / Adjusted EBITDA
©2025 Concentra Inc. All rights reserved. Reconciliation of Net Income to Adjusted EBITDA and Revenue 14 Three Months Ended Mar. 31, TTM Mar. 31, ($ in thousands) 2025 2024 2025 Revenue $500,752 $467,598 $1,933,346 Net Income $40,642 $50,279 $162,260 Income Tax Expense 13,254 15,137 57,613 Interest Expense 25,548 111 73,151 Interest Expense on Related Party Debt — 9,971 12,009 Equity in Earnings of Unconsolidated Subsidiaries — — 3,676 Loss on Early Retirement of Debt 875 — 875 Stock Compensation Expense 2,269 166 4,430 Depreciation and Amortization 16,619 18,485 65,312 Separation Transaction Costs 315 1,993 15 Nova Acquisition Costs 3,137 — 4,032 Adjusted EBITDA $102,659 $96,142 $383,373 Net Income Margin 8.1% 10.8% 8.4% Adjusted EBITDA Margin 20.5% 20.6% 19.8% Note: May not foot due to rounding Normalizing Q1 2024 for a one-time expense reversal, Adj. EBITDA margin was 19.8% in Q1 2024
©2025 Concentra Inc. All rights reserved. Reconciliation of 2025 Full-Year Adjusted EBITDA Guidance 15 Range ($ in millions) Low High Net Income Attributable to the Company $162 $173 Net Income Attributable to Non-Controlling Interests $6 $6 Net Income $168 $179 Income Tax Expense $56 $60 Interest Expense $108 $108 Stock Compensation Expense $10 $10 Depreciation and Amortization $69 $69 Nova Acquisition Costs $4 $4 Adjusted EBITDA $415 $430
